Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
$9.94
$3.49
$10.30
$579.72M2.311.43 million shs1.66 million shs
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$1.04
+9.5%
$1.60
$0.39
$18.00
$4.93M3.625,716 shs408 shs
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$0.08
+13.5%
$0.35
$0.05
$23.40
$402K1.51.21 million shs8,068 shs
Neovasc Inc. stock logo
NVCN
Neovasc
$30.03
$29.69
$4.59
$30.07
$82.28M1.756,993 shs1 shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$2.48
-0.4%
$3.94
$1.03
$5.07
$74.34M2.5181,120 shs111,184 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
0.00%0.00%0.00%0.00%0.00%
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
+9.47%+2.97%-38.82%-62.72%-59.06%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
-6.32%-2.22%-84.91%-89.00%-99.42%
Neovasc Inc. stock logo
NVCN
Neovasc
0.00%0.00%0.00%0.00%0.00%
Neuronetics, Inc. stock logo
STIM
Neuronetics
-2.35%-28.86%-43.79%-30.83%-11.39%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
N/AN/AN/AN/AN/AN/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
1.3596 of 5 stars
3.53.00.00.01.10.00.6
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.9501 of 5 stars
3.33.00.00.01.91.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
N/AN/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
3.00
Buy$28.8836,038.92% Upside
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.50
Moderate Buy$8.00222.58% Upside

Current Analyst Ratings

Latest MOTS, STIM, APEN, NVCN, and ARTH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/26/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/6/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00 ➝ $8.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
$76.86M0.00N/AN/A$0.69 per share0.00
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$80K61.62N/AN/A($2.43) per share-0.43
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$319K1.26N/AN/A$1.74 per share0.05
Neovasc Inc. stock logo
NVCN
Neovasc
$3.81M21.60N/AN/A$5.77 per share5.20
Neuronetics, Inc. stock logo
STIM
Neuronetics
$71.35M1.04N/AN/A$1.18 per share2.10

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
-$39.84M-$1.02N/AN/AN/A-51.84%-89.48%-33.76%N/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
-$6.98MN/A0.00N/A-6,809.45%N/A-386.74%5/20/2024 (Estimated)
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
-$12.87M-$28.55N/AN/A-4,033.54%N/A-110.70%N/A
Neovasc Inc. stock logo
NVCN
Neovasc
-$41.20M-$15.08N/AN/A-1,082.92%-127.25%-80.31%N/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$30.19M-$0.96N/AN/AN/A-42.31%-72.76%-29.25%8/13/2024 (Estimated)

Latest MOTS, STIM, APEN, NVCN, and ARTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/18/2024Q4 2023
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/A-$4.13-$4.13-$3.78N/A$0.06 million
3/5/202412/31/2023
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.26-$0.19+$0.07-$0.19$19.73 million$20.31 million    
2/20/2024Q1 2024
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A-$0.57-$0.57-$0.57N/A$0.05 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
N/AN/AN/AN/AN/A
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/AN/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
1.04
2.35
1.89
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A
0.16
0.04
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
0.46
1.76
1.69
Neovasc Inc. stock logo
NVCN
Neovasc
0.80
2.96
2.85
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.73
4.73
4.33

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
76.01%
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
6.91%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
20.06%
Neovasc Inc. stock logo
NVCN
Neovasc
1.64%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%

Insider Ownership

CompanyInsider Ownership
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
17.30%
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
4.50%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
1.57%
Neovasc Inc. stock logo
NVCN
Neovasc
N/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
9.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
20257.97 million47.94 millionNot Optionable
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
84.74 million4.53 millionNot Optionable
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
155.03 million4.95 millionNot Optionable
Neovasc Inc. stock logo
NVCN
Neovasc
492.74 millionN/ANot Optionable
Neuronetics, Inc. stock logo
STIM
Neuronetics
20329.98 million27.04 millionOptionable

MOTS, STIM, APEN, NVCN, and ARTH Headlines

SourceHeadline
Neuronetics Boasts 12% Revenue Increase, Expands Depression Treatment SectorNeuronetics Boasts 12% Revenue Increase, Expands Depression Treatment Sector
msn.com - May 10 at 11:39 AM
Q2 2024 EPS Estimates for Neuronetics, Inc. Cut by William Blair (NASDAQ:STIM)Q2 2024 EPS Estimates for Neuronetics, Inc. Cut by William Blair (NASDAQ:STIM)
marketbeat.com - May 10 at 6:36 AM
Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results: Heres What Analysts Are Forecasting For This YearNeuronetics, Inc. (NASDAQ:STIM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
finance.yahoo.com - May 9 at 10:36 AM
Neuronetics: Reality Set InNeuronetics: Reality Set In
seekingalpha.com - May 9 at 5:36 AM
Strong Buy Rating for Neuronetics Backed by Solid Financials and Growth ProspectsStrong Buy Rating for Neuronetics Backed by Solid Financials and Growth Prospects
markets.businessinsider.com - May 8 at 7:35 PM
Neuronetics, Inc. (NASDAQ:STIM) Q1 2024 Earnings Call TranscriptNeuronetics, Inc. (NASDAQ:STIM) Q1 2024 Earnings Call Transcript
finance.yahoo.com - May 8 at 7:35 PM
Buy Rating on Neuronetics: Solid Fundamentals and Growth Despite ChallengesBuy Rating on Neuronetics: Solid Fundamentals and Growth Despite Challenges
markets.businessinsider.com - May 8 at 7:50 AM
Neuronetics Inc (STIM) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth Amidst ...Neuronetics Inc (STIM) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth Amidst ...
finance.yahoo.com - May 8 at 7:50 AM
Neuronetics Inc.Neuronetics Inc.
wsj.com - May 8 at 2:49 AM
Neuronetics GAAP EPS of -$0.27 beats by $0.04, revenue of $17.42M beats by $0.3MNeuronetics GAAP EPS of -$0.27 beats by $0.04, revenue of $17.42M beats by $0.3M
msn.com - May 7 at 4:49 PM
STIM Stock Earnings: Neuronetics Beats EPS, Beats Revenue for Q1 2024STIM Stock Earnings: Neuronetics Beats EPS, Beats Revenue for Q1 2024
msn.com - May 7 at 4:49 PM
Neuronetics Inc (STIM) Reports Q1 2024 Earnings: Revenue Surpasses Estimates, Narrowing LossesNeuronetics Inc (STIM) Reports Q1 2024 Earnings: Revenue Surpasses Estimates, Narrowing Losses
finance.yahoo.com - May 7 at 4:49 PM
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue EstimatesNeuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
zacks.com - May 7 at 9:41 AM
Neuronetics Reports Record First Quarter 2024 Financial and Operating ResultsNeuronetics Reports Record First Quarter 2024 Financial and Operating Results
globenewswire.com - May 7 at 7:30 AM
Neuronetics Q1 2024 Earnings PreviewNeuronetics Q1 2024 Earnings Preview
msn.com - May 6 at 7:58 PM
Neuronetics (STIM) to Release Quarterly Earnings on TuesdayNeuronetics (STIM) to Release Quarterly Earnings on Tuesday
americanbankingnews.com - May 5 at 4:46 AM
Neuronetics, Inc. (STIM)Neuronetics, Inc. (STIM)
finance.yahoo.com - May 4 at 11:57 PM
Neuronetics Awards Stock Options to New Employees as InducementNeuronetics Awards Stock Options to New Employees as Inducement
msn.com - May 4 at 5:53 PM
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - May 3 at 4:30 PM
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness MonthNeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
globenewswire.com - May 1 at 8:31 AM
Neuronetics, Inc. (NASDAQ:STIM) Sees Large Drop in Short InterestNeuronetics, Inc. (NASDAQ:STIM) Sees Large Drop in Short Interest
marketbeat.com - April 27 at 3:07 PM
Neuronetics Announces Q1 2024 Earnings Release and Conference CallNeuronetics Announces Q1 2024 Earnings Release and Conference Call
msn.com - April 25 at 12:04 PM
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference CallNeuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
globenewswire.com - April 23 at 4:30 PM
Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%
marketbeat.com - April 12 at 3:58 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Apollo Endosurgery logo

Apollo Endosurgery

NASDAQ:APEN
Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.
Arch Therapeutics logo

Arch Therapeutics

OTCMKTS:ARTH
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.
Motus GI logo

Motus GI

NASDAQ:MOTS
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.
Neovasc logo

Neovasc

NASDAQ:NVCN
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.
Neuronetics logo

Neuronetics

NASDAQ:STIM
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.